Venture funds support combination treatment for dyskinesia

Wednesday 13 June 2012

A preclinical drug combination treatment that is being positioned to treat dyskinesia has received €1.3 million in new funding from two Danish investment groups, SEED Capital and Novo Seeds, a unit of the Novo Nordisk Foundation.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark